<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04523857</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 10119</org_study_id>
    <nct_id>NCT04523857</nct_id>
  </id_info>
  <brief_title>ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer</brief_title>
  <acronym>ABBY</acronym>
  <official_title>A Phase II Pilot Trial of ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer Patients (&quot;ABBY&quot;)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II randomized, controlled, open label breast cancer clinical trial. 66&#xD;
      patients will be enrolled. The drugs being studied are hydroxychloroquine (Plaquenil) and&#xD;
      abemaciclib (also Verzenio). This research study is testing whether using these drugs to&#xD;
      target the disseminated tumor cells in bone marrow can reduce their number or eliminate them.&#xD;
      Both hydroxychloroquine and abemaciclib are pills that will be taken twice daily. Both are&#xD;
      approved by the FDA&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">December 2027</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events during cycle 1 of the safety cohort (safety of combination HCQ + Abema)</measure>
    <time_frame>Toxicity is assessed over the first cycle (4 weeks) of treatment</time_frame>
    <description>Rate of protocol defined &quot;severe toxicity&quot; during cycle 1 (4 weeks) of combination HCQ 600mg BID and Abema (at 100 mg and 150 mg BID) in a safety cohort of 6 patients at each dose of Abema</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in bone marrow DTC number evaluated by DTC-IHC assay after 6 cycles of therapy compared to baseline (Efficacy of Abema +/- HCQ in eliminating bone marrow DTCs)</measure>
    <time_frame>6 cycles (approximately 6 months)</time_frame>
    <description>Frequency of &quot;clearance&quot; of bone marrow DTCs by arm after 6 cycles of study treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A (Abema)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abemaciclib (150 mg BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B (Abema + HCQ)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abemaciclib (100 mg or 150 mg BID*) + Hydroxychloroquine (600 mg BID)&#xD;
*Abemaciclib dose will be determined by safety cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib</intervention_name>
    <description>Oral CDK4/6 inhibitor to target bone marrow disseminated tumor cells (DTCs)</description>
    <arm_group_label>A (Abema)</arm_group_label>
    <arm_group_label>B (Abema + HCQ)</arm_group_label>
    <other_name>Verzenio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Oral autophagy inhibitor to target bone marrow disseminated tumor cells (DTCs)</description>
    <arm_group_label>B (Abema + HCQ)</arm_group_label>
    <other_name>Plaquenil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically-confirmed, primary, invasive breast cancer diagnosed within 5 years of&#xD;
             entry into a companion DTC screening protocol.&#xD;
&#xD;
          -  Qualifying risk status, at diagnosis utilizing receptor testing by ASCO/CAP guidelines&#xD;
&#xD;
          -  Patients must have completed all primary therapy for the index malignancy at least 4&#xD;
             weeks prior to study entry. Prior treatment-related toxicity must be resolved or&#xD;
             improving to Grade 1 with the exception of alopecia and up to Grade 3 peripheral&#xD;
             neuropathy, prior to study enrollment. Concurrent receipt of adjuvant endocrine and&#xD;
             bone modifying agents is allowed per standard of care guidelines. Tamoxifen is not&#xD;
             allowed due to drug-drug interactions with HCQ.&#xD;
&#xD;
          -  Bone marrow aspirate after completion of therapy demonstrates detectable DTCs (via&#xD;
             IHC)&#xD;
&#xD;
          -  No evidence of recurrent local or distant breast cancer by physical examination, blood&#xD;
             tests or symptom-directed imaging, per NCCN guidelines.&#xD;
&#xD;
          -  ECOG performance status =/&lt; 2&#xD;
&#xD;
          -  Ability to swallow oral medications&#xD;
&#xD;
          -  No contraindications to the study medications or uncontrolled medical illness.&#xD;
&#xD;
          -  Adequate bone marrow function&#xD;
&#xD;
          -  Adequate liver function&#xD;
&#xD;
          -  Adequate renal function&#xD;
&#xD;
          -  Anticoagulation is allowed if target INR =/&lt; 1.5 on a stable dose of warfarin or on a&#xD;
             stable dose of anticoagulant for &gt;2 weeks at time of randomization&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Concurrent enrollment on another investigational therapy&#xD;
&#xD;
          -  Prior treatment with a CDK 4/6 inhibitor&#xD;
&#xD;
          -  Known hypersensitivity to hydroxychloroquine or any of its derivatives&#xD;
&#xD;
          -  Patients with hormone-receptor positive breast cancer may not be receiving tamoxifen&#xD;
             due to drug-drug interactions with hydroxychloroquine&#xD;
&#xD;
          -  Patients who have received bone modifying agents within 3 months&#xD;
&#xD;
          -  Patients who have any severe and/or uncontrolled medical conditions or other&#xD;
             conditions that could affect their participation in the study&#xD;
&#xD;
          -  Female patients who are pregnant or breast feeding, or adults of reproductive&#xD;
             potential who are not using effective birth control methods.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test within 7&#xD;
             days prior to the first dose of Abema&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Clark, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lauren Bayne, PhD</last_name>
    <phone>215-349-5398</phone>
    <email>lajesse@pennmedicine.upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Bayne, PhD</last_name>
      <phone>215-349-5398</phone>
      <email>lajesse@pennmediicne.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Amy Clark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 6, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2020</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm, Residual</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

